Sickle Cell Disease Trial, Recruiting (NCT06374238)

Sickle Cell Disease Trial, Recruiting NCT06374238 Sponsor: University of Pittsburgh Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06374238 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 16 and 30 years old at the time of joining the trial
You have been diagnosed with sickle cell disease (any type/form)
You experience ongoing pain at least 4 days a week for the past 3 months or more, OR you have been prescribed pain medication taken at least 4 days a week for 3 or more months, OR you take pain medication at least 4 days a week for 3 or more months, OR you receive non-medication pain treatment at least 4 days a week for 3 or more months
You have access to a smartphone (iPhone or Android) with internet access

Who may not be able to join:

You are unable to speak or read English
You have previously had a stem cell transplant (a procedure using donor stem cells) as a treatment for sickle cell disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Charles Jonassaint, PhD, University of Pittsburgh

Phone: 877-649-0176

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06374238

Sponsor: University of Pittsburgh

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: 877-649-0176

More information: https://clinicaltrials.gov/study/NCT06374238

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 16 and 30 years old at the time of joining the trial
You have been diagnosed with sickle cell disease (any type/form)
You experience ongoing pain at least 4 days a week for the past 3 months or more, OR you have been prescribed pain medication taken at least 4 days a week for 3 or more months, OR you take pain medication at least 4 days a week for 3 or more months, OR you receive non-medication pain treatment at least 4 days a week for 3 or more months
You have access to a smartphone (iPhone or Android) with internet access

Who may not be able to join:

You are unable to speak or read English
You have previously had a stem cell transplant (a procedure using donor stem cells) as a treatment for sickle cell disease

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Pittsburgh

Registry

ClinicalTrials.gov

Start date

10 March 2025

Est. completion

1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Determine the effectiveness of any digital CBT (CBT + peer or self-guided CBT) vs usual care (UC) to improve pain intensity for AYAs with SCD and chronic pain; Determine the effectiveness of any digital CBT (CBT + peer or self-guided CBT) vs usual care (UC) to improve pain interference for AYAs with SCD and chronic pain

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov